Sitryx Therapeutics patents new NRF2 activators for inflammatory disorders

Jan. 16, 2024

Sitryx Therapeutics Ltd. has disclosed nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators reported to be useful for the treatment of inflammatory disorders.

BioWorld Science Inflammatory Patents

Today's news in brief

BioWorld

BioWorld briefs for April 1, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 1, 2025.

Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal

BioWorld Science

As companies continually search for next-generation obesity prospects, one of the leaders in the disease space, Novo Nordisk A/S, has obtained an exclusive...

Corcept looks to NDA following strong phase III ovarian cancer data

BioWorld

Relacorilant, a cortisol modulator from Corcept Therapeutics Inc., produced new and strong phase III results in treating platinum-resistant ovarian cancer. The...

Otsuka submits first BLA to FDA for sibeprenlimab in IgAN

BioWorld

Otsuka Pharmaceutical Development & Commercialization Inc. filed its BLA with the U.S. FDA for sibeprenlimab to treat immunoglobulin A nephropathy (IgAN). The...